The FDA approval of Biogen’s Aduhelm for Alzheimer’s has breathed new life into neurology models throughout biopharma, none extra so than nearest rival Eli Lilly. Trying to experience that constructing wave, Lilly is prepared for a brand new look.
Lilly will break up its bigger Bio-Medicines enterprise, propping up new neuroscience and immunology models as a part of a broad reorganization of the Indianapolis drugmaker’s pipeline centered, partially, round late-stage Alzheimer’s candidate donanemab, the corporate introduced Tuesday.
Hold studying Endpoints with a free subscription
Unlock this story immediately and be part of 114,600+ biopharma professionals studying Endpoints every day — and it is free.